CN115227616A - Composition with antioxidation effect, application and cosmetic - Google Patents

Composition with antioxidation effect, application and cosmetic Download PDF

Info

Publication number
CN115227616A
CN115227616A CN202210938458.6A CN202210938458A CN115227616A CN 115227616 A CN115227616 A CN 115227616A CN 202210938458 A CN202210938458 A CN 202210938458A CN 115227616 A CN115227616 A CN 115227616A
Authority
CN
China
Prior art keywords
composition
ectoin
leaf extract
olive leaf
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210938458.6A
Other languages
Chinese (zh)
Inventor
戴丽云
杨凝真
吴越
陈帆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bloomage Biotech Co Ltd
Original Assignee
Bloomage Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bloomage Biotech Co Ltd filed Critical Bloomage Biotech Co Ltd
Priority to CN202210938458.6A priority Critical patent/CN115227616A/en
Publication of CN115227616A publication Critical patent/CN115227616A/en
Priority to CN202211405109.4A priority patent/CN115501153A/en
Priority to CN202211405101.8A priority patent/CN115487120A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

Provided is a composition having an antioxidant effect, which comprises ectoin or a derivative thereof and an olive leaf extract. According to the application, the ectoin and the olive leaf extract are combined, so that the oxidation resistance can be obviously improved, the effect of high usage amount of ectoin is still achieved under the condition of reducing the usage amount of ectoin, and the raw material cost is reduced.

Description

Composition with antioxidation effect, application and cosmetic
Technical Field
The application relates to the technical field of cosmetics, in particular to a composition with an antioxidation effect, an application and a cosmetic.
Background
Usually, exogenous chemicals, heavy metals, UV radiation are the main causes of oxidative stress to the skin. Such stimulation and cellular oxidative metabolism can produce Reactive Oxygen Species (ROS), causing intracellular and extracellular oxidative stress reactions, which can cause a series of skin problems. These include induction of inflammation, impaired skin barrier function, acceleration of lipid secretion and pigmentation, and even promotion of expression of Metal Matrix Proteases (MMPs) in the dermis, leading to collagen breakdown. Therefore, it is important to remove excessive ROS in skin, and various antioxidant substances are adopted in the current cosmetics to resist the damage of ROS, including: vitamin E, vitamin C, tocopherol, etc.
Ectoin, named as tetrahydro-methyl pyrimidine carboxylic acid in Chinese, is Ectoine corresponding to the name of INCI, is separated from the extreme halophilic ectothiospira earliest, has good hydrophilicity, does not interfere most enzymatic reactions in cells, has high intracellular tolerance and is stable to heat.
However, in the existing cosmetics, the ectoine is expensive, and the addition amount of the ectoine in the cosmetics is large, so that the cosmetics containing the ectoine are high in cost and expensive.
Disclosure of Invention
In view of the problems of the prior art, the present application provides a composition having an anti-oxidative effect, which comprises ectoin or a derivative thereof and an olive leaf extract. The composition can reduce the usage amount of ectoin, save the raw material cost and realize excellent antioxidant effect.
Solution scheme
1. A composition having an antioxidant effect, wherein the composition comprises ectoin or a derivative thereof and an olive leaf extract.
2. The composition according to item 1, wherein the mass ratio of the ectoin or derivative thereof to the olive leaf extract is 1: (1-800).
3. The composition according to any one of items 1 to 2, wherein the derivative of ectoin comprises one or more of methyl tetrahydropyrimidine, hydroxyectoin (1, 4,5, 6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid), ectoin sodium salt, and ectoin potassium salt.
4. Use of the composition according to any one of claims 1 to 3 for the preparation of an antioxidant ingredient.
5. The use according to item 4, wherein the antioxidant ingredient is used in cosmetics.
6. A cosmetic composition comprising the composition according to any one of items 1 to 3.
7. The cosmetic of item 6, wherein the composition is in a mass percentage of 0.1 to 10wt% based on the total weight of the cosmetic.
8. The cosmetic of item 6, wherein the cosmetic further comprises an adjuvant.
Technical effects
(1) According to the application, the antioxidant performance can be obviously improved by combining the ectoin and the olive leaf extract.
(2) According to the application, the ectoin and the olive leaf extract are combined, so that the effect of high usage of the ectoin is still achieved under the condition of reducing the usage of the ectoin, and the raw material cost is reduced.
Detailed Description
The present application is further described below in conjunction with the following examples, which are intended to be illustrative and explanatory only and are not restrictive of the application.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in experimental or practical applications, the materials and methods are described below. In case of conflict, the present specification, including definitions, will control, and the materials, methods, and examples are illustrative only and not intended to be limiting. The present application is further described with reference to the following specific examples, which should not be construed as limiting the scope of the present application.
Provided is a composition having an antioxidant effect, which comprises ectoin or a derivative thereof and an olive leaf extract.
The ectoin is also called salt-tolerant bacteria extract liquid, is derived from high halophilic bacteria (Halomonas Elongata), is a small-molecular cyclic amino acid derivative, is mostly an osmotic pressure compensation solute synthesized by extreme environment microorganisms under osmotic pressure stress, and can prevent the halophilic bacteria from being damaged under the extreme conditions of high salt, high temperature and high ultraviolet radiation. At present, the main action and mechanism of action of ectoin or its derivatives have been studied as follows:
1. moisture retention effect
The mechanism is as follows: the intensive charge distribution on the surface of the molecule of the ectoin or the derivative thereof further strengthens the hydrogen bond function between water molecules through the electrostatic action between the ectoin or the derivative thereof and the water molecules, reduces the water activity, promotes the formation of a more stable water compound and achieves the effects of moisturizing and long-acting moisturizing.
2. Protection of biomolecules and cells
Including stabilizing proteins, reducing damage to DNA from electromagnetic radiation, enhancing cell membrane stability and fluidity, inhibiting UV-induced cell damage (mitochondrial gene mutation, nuclear DNA damage, etc.), and reducing damage to cells from adverse environments such as high temperature and UV.
The mechanism is as follows: the ectoin or the derivative thereof is combined with water molecules to form a stable water complex, so that the stability of protein can be effectively improved, phospholipid bilayers (cell membranes) and DNA (deoxyribonucleic acid) can be protected, and damage of adverse environments to cells is reduced due to protection of biological macromolecules.
3. Anti-inflammatory action
The mechanism is as follows: the ectoin or the derivative thereof can reduce the expression of proinflammatory factors and inflammatory factors and block inflammatory reaction; the ectoin or the derivative thereof protects biomolecules and cells, reduces the damage of external unfavorable stimulation (high temperature, UV and the like) to the cells, and enhances the stress resistance of the cells; the ectoin or the derivative thereof protects immune cells and improves the autoimmune capability of the body.
4. Whitening effect
The mechanism is as follows: inhibiting the synthesis of melanin, and inhibiting the expression of genes related to the synthesis of melanin and protein secretion in melanoma cells of human and mice to a certain extent.
5. Repairing action
The mechanism is that Ectoine can promote the expression of heat stress protein (hsp 70) gene under the condition of no heat shock and activate the heat stress reaction of cells by the mode, so as to protect and repair cells and tissues and improve the tolerance of the cells.
6. Other possible effects: promoting correct folding of proteins (for degenerative neurological diseases).
The ectoin or the derivative thereof has obvious effect as an effective component, and the problem of yield is always concerned due to limited sources, complex process modes and great attention, so that the price is difficult to reduce, and the addition amount is small, the effect is not obvious, and the cost of the cosmetics is overhigh due to the excessive addition amount when the ectoin or the derivative thereof is added into the cosmetics.
The folium Canarii albi extract has antioxidant, anti-tumor, blood sugar lowering, blood lipid reducing, antiinflammatory and analgesic effects. Although the olive leaf extract has the above-mentioned effects, it is not suggested that it can significantly improve the above-mentioned effects of other ingredients, much less that it can effectively down-regulate the amount of ectoin or its derivatives used in cosmetics.
The composition with the antioxidation effect comprises ectoin and olive leaf extract, wherein the composition is used as an antioxidation component in cosmetics; and active oxygen free radicals in cells are eliminated under specific concentration, thereby achieving synergistic antioxidant effect.
In some embodiments of the present application, the composition consists of ectoin or a derivative thereof and olive leaf extract.
In some embodiments of the present application, the mass ratio of the ectoin or derivative thereof to the olive leaf extract is 1: (1-800), preferably 1: (50-800), more preferably 1: (100-800), still more preferably 1: (200-800).
1, the ratio of the mass of the olive to the mass of the component.
As is apparent to those skilled in the art, addition of ectoin or a derivative thereof as an effective ingredient to cosmetics is effective, but it is expensive, and when it is added to cosmetics, the addition amount of ectoin or a derivative thereof is too low, the effect is not significant, and if it is too high, the cost of cosmetics is high. The olive leaf extract has wide source and low cost. Therefore, in the present application, the synergistic effect of ectoin or a derivative thereof and olive leaf extract is studied, and the ratio of both is controlled so that the effect at a high addition level when ectoin or a derivative thereof is added alone can be achieved or exceeded at a low addition level of ectoin or a derivative thereof.
In the present application, ectoin or a derivative thereof may be added to the cosmetic in an amount of 0.001wt% to 0.5wt%, preferably 0.002wt% to 0.1wt%, and more preferably 0.0025wt% to 0.05wt%, for example, the ectoin or a derivative thereof is added in an amount of 0.001wt%, 0.002wt%, 0.003wt%, 0.004wt%, 0.005wt%, 0.006wt%, 0.007wt%, 0.008wt%, 0.009wt%, 0.01wt%, 0.02wt%, 0.03wt%, 0.04wt%, 0.05wt%, 0.06wt%, 0.07wt%, 0.08wt%, 0.09wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, or any range therebetween.
In the present application, the olive leaf extract may be added to the cosmetic in an amount of 0.01wt% to 8wt%, for example, 0.01wt%, 0.02wt%, 0.03wt%, 0.04wt%, 0.05wt%, 0.06wt%, 0.07wt%, 0.08wt%, 0.09wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1.0wt%, 2.0wt%, 3.0wt%, 4.0wt%, 5.0wt%, 6.0wt%, 7.0wt%, 8.0wt%, or any range therebetween.
In some embodiments of the present application, the derivative of ectoin comprises one or more of methyl tetrahydropyrimidine, hydroxy ectoin (1,4,5,6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid), ectoin sodium salt, ectoin potassium salt.
In some embodiments of the present application, the olive leaf extract may be purchased commercially or may be extracted by itself. Commercially available products include, but are not limited to, draco olive leaf extract concentrate, HALLSTAR Olea europaea extract, berkel SAS Olea europaea extract. The self-extracting method is a method commonly used for extracting olive leaves, and the extracting method is not particularly limited as long as the olive leaf extract has conventional efficacy, for example, the olive leaves are extracted by using a solvent, or the solvent and ultrasonic assistance and/or biological enzyme are matched with each other, and the solvent can be water and/or alcohol. For example, the crushed olive leaves may be extracted with water and/or ethanol as an extraction solvent; or extracting pulverized folium Canarii albi with water and/or ethanol as extraction solvent, adding biological enzyme and/or ultrasound.
In a specific embodiment of the application, olive leaves are dried in the shade, crushed and dissolved in ethanol, the materials are mixed and homogenized in a homogenizer, the homogenized materials are placed in an ultrasonic device, and proper ethanol solution is added for ultrasonic extraction to obtain concentrated solution; eluting the obtained concentrated solution, collecting eluate, concentrating, and drying to obtain folium Canarii albi extract.
In a specific embodiment of the application, olive leaves are dried in the shade, crushed and dissolved in water, the olive leaves are mixed and homogenized in a homogenizer, the homogenized material is placed in an ultrasonic device, and a proper aqueous solution is added for ultrasonic extraction to obtain a concentrated solution; eluting the obtained concentrated solution, collecting eluate, concentrating, and drying to obtain folium Canarii albi extract.
The application provides the use of the composition in the preparation of an antioxidant ingredient.
Further, the antioxidant ingredient can be used in skin care products.
The present application provides a cosmetic comprising the above composition.
In some embodiments herein, the composition is present in an amount of 0.1 to 10wt% based on the total weight of the cosmetic;
for example, the composition can be 0.1wt%, 0.5wt%, 1wt%, 1.5wt%, 2.0wt%, 2.5wt%, 3.0wt%, 3.5wt%, 4.0wt%, 4.5wt%, 5.0wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, or any range therebetween, by mass percent.
In some embodiments of the present application, the cosmetic further comprises an adjuvant comprising one or more of a solvent, a humectant, a chelating agent, an emollient, a skin conditioner, an emulsifier, a fragrance, a preservative, a thickener, a pH adjuster.
In some embodiments of the present application, the cosmetic includes, but is not limited to, any one of skin lotion, skin essence, skin lotion, skin cream, makeup color, soap, facial cleanser, body wash, skin gel, essence, eye cream, and facial mask.
In the application, the ectoin and the olive leaf extract are combined and applied to HaCaT cells to effectively inhibit H 2 O 2 Induced ROS generation, and antioxidant synergistic effect. According to the application, the ratio of the ectoin or the derivative thereof to the olive leaf extract is further regulated and controlled, so that the effect of high addition amount when the ectoin or the derivative thereof is added independently can be achieved when the addition amount of the ectoin or the derivative thereof is low, and the use cost of the ectoin or the derivative thereof is reduced.
Examples
The materials used in the tests and the test methods are generally and/or specifically described in the present application and in the following examples,% means wt%, i.e. percent by weight, unless otherwise specified. The reagents or instruments used are conventional reagent products which are commercially available, and manufacturers are not indicated.
Example 1
HaCaT cell complete medium: DMEM medium (containing 10% FBS, 1% streptomycin)
Ectoin (hereinafter abbreviated as Ectoine, purchased from Hippocampus) was added to HaCaT medium and dissolved to obtain fraction A.
Dissolving folium Canarii albi extract (hereinafter referred to as OLE, draco Natural Products, SDNP-0034001109) in HaCaT culture medium to obtain component B.
And uniformly mixing the component A and the component B to obtain the composition, wherein in the composition, the weight percentage of the ectoin to the total weight of the composition is 0.05wt%, the weight percentage of the olive leaf extract to the total weight of the composition is 2wt%, and the weight ratio of the ectoin to the olive leaf extract is 1 (E+O)1 。
Example 2
Example 2 differs from example 1 only in that the olive leaf extract represents 1wt% of the total weight of the composition, the mass ratio of ectoin to olive leaf extract is 1 (E+O)2 The other conditions were the same.
Example 3
Example 3 differs from example 1 only in that the olive leaf extract represents 0.5wt% of the total weight of the composition, the mass ratio of ectoin to olive leaf extract is 1 (E+O)3 The other conditions were the same.
Example 4
Example 4 differs from example 1 only in that the percentage by mass of the olive leaf extract relative to the total weight of the composition is 0.05wt%, the mass ratio of ectoine to olive leaf extract, denoted T1 (E+O)4 The other conditions were the same.
Example 5
Example 5 differs from example 1 only in that, based on the total weight of the composition, the weight percentage of ectoin to the total weight of the composition is 0.01wt%, the weight percentage of olive leaf extract to the total weight of the composition is 2wt%, and the weight ratio of ectoin to olive leaf extract, denoted as T200 (E+O)5 The other conditions were the same.
Example 6
Example 6 differs from example 5 only in that the olive leaf extract represents 1wt% of the total weight of the composition, the mass ratio of ectoin to olive leaf extract is 1 (E+O)6 The other conditions were the same.
Example 7
Example 7 differs from example 5 only in that the percentage by mass of the olive leaf extract relative to the total weight of the composition is 0.5wt%, the mass ratio of ectoine to olive leaf extract, denoted T1 (E+O)7 The other conditions were the same.
Example 8
Example 8 differs from example 5 only in that the olive leaf extract represents 0.05wt% of the total weight of the composition, the weight ratio of ectoin to olive leaf extract is 1 (E+O)8 The other conditions were the same.
Example 9
Example 9 differs from example 1 only in that, based on the total weight of the composition, the weight percentage of ectoin to the total weight of the composition is 0.005wt%, the weight percentage of olive leaf extract to the total weight of the composition is 2wt%, and the weight ratio of ectoin to olive leaf extract, denoted as T400 (E+O)9 The other conditions were the same.
Example 10
Example 10 differs from example 9 only in that the percentage by mass of the olive leaf extract relative to the total weight of the composition is 1wt%, the mass ratio of ectoin to the olive leaf extract is 1 (E+O)10 The other conditions were the same.
Example 11
Example 11 differs from example 9 only in that the olive leaf extract represents 0.5wt% of the total weight of the composition, the weight ratio of ectoin to olive leaf extract is 1 (E+O)11 The other conditions were the same.
Example 12
Example 12 differs from example 9 only in that the olive leaf extract represents 0.05wt% of the total weight of the composition, the weight ratio of ectoin to olive leaf extract is 1 (E+O)12 The other conditions were the same.
Example 13
Example 13 differs from example 1 only inThen, based on the total weight of the composition, the weight percentage of the ectoin to the total weight of the composition is 0.0025wt%, the weight percentage of the olive leaf extract to the total weight of the composition is 2wt%, and the weight ratio of the ectoin to the olive leaf extract is 1 (E+O)13 The other conditions were the same.
Example 14
Example 14 differs from example 9 only in that the olive leaf extract represents 1wt% of the total weight of the composition, the mass ratio of ectoin to olive leaf extract is 1 (E+O)14 The other conditions were the same.
Example 15
Example 15 differs from example 9 only in that the olive leaf extract represents 0.5wt% of the total weight of the composition, the weight ratio of ectoin to olive leaf extract is 1 (E+O)15 The other conditions were the same.
Example 16
Example 16 differs from example 9 only in that the olive leaf extract represents 0.05wt% of the total weight of the composition, the weight ratio of ectoin to olive leaf extract is 1 (E+O)16 The other conditions were the same.
Comparative example 1
Comparative example 1 differs from example 1 only in that in the composition, ectoin represents 0.05wt% of the total weight of the composition, based on the total weight of the composition, and does not contain olive leaf extract, denoted T E1 The other conditions were the same.
Comparative example 2
Comparative example 2 differs from example 1 only in that in the composition, ectoin is 0.01wt% based on the total weight of the composition, and olive leaf extract, denoted T, is not present E2 The other conditions were the same.
Comparative example 3
Comparative example 3 differs from example 1 only in that in the composition, ectoin represents the mass of the total weight of the compositionPercentage 0.005wt%, no olive leaf extract, marked T E3 The other conditions were the same.
Comparative example 4
Comparative example 4 differs from example 1 only in that in the composition, ectoin is present in an amount of 0.0025wt% based on the total weight of the composition, and olive leaf extract, denoted T, is not present E4 The other conditions were the same.
Comparative example 5
Comparative example 5 differs from example 1 only in that in the composition, the olive leaf extract represents 2wt% of the total weight of the composition, and does not contain ectoin, denoted as T, based on the total weight of the composition O1 The other conditions were the same.
Comparative example 6
Comparative example 6 differs from example 1 only in that in the composition, the olive leaf extract represents 1wt% of the total weight of the composition, and does not contain ectoin, denoted as T O2 The other conditions were the same.
Comparative example 7
Comparative example 7 differs from example 1 only in that in the composition, the olive leaf extract accounts for 0.5wt% of the total weight of the composition, does not contain ectoin, and is marked as T O3 The other conditions were the same.
Comparative example 8
Comparative example 8 differs from example 1 only in that in the composition, the olive leaf extract accounts for 0.05wt% of the total weight of the composition, does not contain ectoin, and is marked as T O4 The other conditions were the same.
Comparative example 9
Comparative example 9 differs from example 1 only in that in the composition, ectoin is 0.1wt% based on the total weight of the composition, and olive leaf extract, denoted T, is not present E5 The other conditions were the same.
Table 1 shows the material compositions of example 1 to example 16, comparative example 1 to comparative example 9.
TABLE 1
Figure BDA0003784611900000101
Figure BDA0003784611900000111
Note: in the combination name, E represents Ectoine, O represents olive leaf extract OLE, and E + O represents the combination of Ectoine and olive leaf extract OLE.
Examples of the experiments
EXAMPLE 1 composition H 2 O 2 Effect on HaCaT cell Activity under oxidative stress
The test method comprises the following steps: haCaT cells were incubated for 1 day with media containing various concentrations of the active of the panel and then incubated with 0.5mM H 2 O 2 The solution is treated for 16 hours, the culture medium is removed, MTT is added, after 3 hours, the supernatant is carefully aspirated, dimethyl sulfoxide (DMSO) is added, OD value detection is carried out at 550nm by using a microplate reader, after the background is removed by reading, relative activity rate of cells is expressed by percentage by taking a control group as a reference after homogenization. The experimental groups are all diluted by HaCaT cell culture medium, and a blank group 1 is arranged and B is used 1 Is shown (not with H) 2 O 2 Treatment), control 1 with CN 1 Is shown (with H only) 2 O 2 Treatment) the relative activity rate of the cells was determined to be 100%. Define the experimental group as T E (Ectoine independent treatment), T O (OLE Individual treatment), T E+O (Ectoine and OLE mixed treatment), the relative activity of the cells of the experimental group minus the relative activity of the cells of the control group is taken as the corresponding cell proliferation rate.
Since 0.5mM of H was used during the experiment 2 O 2 The cells are treated by the solution for 16h, sufficient scientific theoretical data are provided for subsequent experimental results, whether the step has influence on the activity of the HaCaT cells is researched, and therefore the blank group B and the control group are analyzedCN data are shown in Table 2.
TABLE 2
Figure BDA0003784611900000112
Figure BDA0003784611900000121
As can be seen from Table 2, blank group B 1 And a control group CN 1 With no statistical difference between them, 0.5mM H 2 O 2 The effect on the activity of HaCaT cells after solution treatment was not considered.
After the addition of the sample to be tested, further analysis can be carried out, for example: the cell proliferation rate was 6% when only 0.05wt% ectoin (Ectoine-0.05 wt%) was used (comparative example 1), and 9% when only 2wt% olive leaf extract (OLE-2 wt%) was used (comparative example 5); when a composition of 0.05wt% ectoin and 2wt% olive leaf extract (Ectoine-0.05 wt% + OLE-2 wt%) was used, the cell proliferation rate was 18%.
To illustrate the synergistic effect of the composition, we used the formula of gold: q = E (a + b)/(Ea + Eb-Ea × Eb) (where Q <0.55 is a clear antagonism, Q = 0.55-0.85 is an antagonism, Q = 0.85-1.15 is an addition, Q >1.15 is an enhancement) for validation.
Using example 1 as an example, ea = (Ectoine-0.05 wt%) cell proliferation rate =6%; eb = (OLE-2 wt%) cell proliferation rate =9%; the cell proliferation rate of E (a + b) = (Ectoine-0.05 wt% + OLE-2 wt%) =18%, and Q for the cell proliferation rate of example 1 was obtained by substituting the formula of King (Ectoine-0.05wt％+OLE-2wt％) =1.2448. The Q value of the cell growth rate of each example was also obtained according to the above-mentioned gold formula. As can be seen from Table 2, the compositions of the examples of the present application are effective in enhancing H 2 O 2 The cell activity under pressure has better synergistic effect.
Experimental example 2 ROS content detection
The test method comprises the following steps: haCaT cells were seeded at 30000/well in 96-well platesIn, at 37 ℃ and 5% CO 2 Culturing under the condition for later use. After the cells adhere to the wall, the prepared sample groups are added in sequence at 100 mu L/hole after 24 h. After the incubation was complete, the supernatant was aspirated off and 200. Mu.L of 1mM H was added to each well 2 O 2 The solution (blank group 2 with phenol red free medium), incubated for 15min, washed once with PBS, added 10. Mu.M of DCFH-DA working solution 200. Mu.L, incubated for 30min. The fluorescence intensity was measured at an excitation wavelength of 485nm and an emission wavelength of 538nm using a fluorescence microplate reader. After background subtraction of readings, control 2 (H alone) was used 2 O 2 Treatment) was used as a benchmark, and the relative ROS content was expressed as a percentage after homogenization. The experimental groups are all diluted by HaCaT cell culture medium, and a blank group 2 is arranged and B is used 2 Denotes (not using H) 2 O 2 Treatment), control 2 with CN 2 Is shown (with H only) 2 O 2 Treatment) the relative content of ROS was defined as 100%. Define the experimental group as T E (Ectoine treatment alone), T O (OLE separate processing), T E+O (mixed Ectoine and OLE treatment), the relative ROS content of the experimental group is subtracted by the 2CN of the control group 2 The absolute value after the relative amount of ROS is taken as the corresponding ROS inhibition rate. The results are shown in Table 3.
TABLE 3
Figure BDA0003784611900000131
Figure BDA0003784611900000141
As can be seen from Table 3, 1mM of H was used during the experiment 2 O 2 Treating the cells with the solution for 15min to provide sufficient scientific theoretical data for subsequent experimental results, and investigating whether the step has influence on ROS generation, thereby analyzing blank group B 2 And a control group CN 2 The data of (1). From Table 3 above, blank set B was analyzed 2 And a control group CN 2 The data of (1) found that the cells cultured normally had H 2 O 2 The ROS content of the solution-treated cells differed considerably, thus giving 1mM H 2 O 2 Solution treatment of the cells for 15min can better stimulate the cells to generate ROS.
After addition of the test sample, further analysis can be carried out, for example: the ROS inhibition rate was 10% when only 0.05wt% of ectoin (Ectoine-0.05 wt%) was used, 10% when only 2wt% of olive leaf extract (OLE-2 wt%) was used, and 22% when 0.05wt% of ectoin was used in the composition and 2wt% of olive leaf extract (Ectoine-0.05 wt% + OLE-2 wt%).
To illustrate the synergistic effect of the composition, we used the formula of gold: q = E (a + b)/(Ea + Eb-Ea × Eb) (where Q <0.55 is significant antagonism, Q = 0.55-0.85 is antagonism, Q = 0.85-1.15 is additive, Q >1.15 is enhanced).
Using example 1 as an example, ea = (ecotoine-0.05 wt%) ROS inhibition =10%; eb = (OLE-2 wt%) ROS inhibition =10%; ROS inhibition of E (a + b) = (Ectoine-0.05 wt% + OLE-2 wt%) =22%, Q substituted into the formula to obtain ROS inhibition (Ectoine-0.05wt％+OLE-2wt％) =1.1579. The Q value of the ROS inhibition ratio of each of the above examples was also obtained by the above formula. The above results illustrate that: the composition disclosed by the embodiment of the application can effectively inhibit the generation of ROS, and a synergistic effect is obtained.
Although the present disclosure has been described with reference to particular embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure, and the scope of the present disclosure should be limited only by the terms of the appended claims.

Claims (8)

1. A composition having an antioxidant effect, characterized in that,
the composition comprises ectoin or a derivative thereof and olive leaf extract.
2. The composition of claim 1,
the mass ratio of the ectoin or the derivative thereof to the olive leaf extract is 1: (1-800).
3. The composition according to any one of claims 1 to 2,
the derivatives of ectoine comprise one or more than two of methyl tetrahydropyrimidine, hydroxy ectoine (1, 4,5, 6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid), ectoine sodium salt and ectoine potassium salt.
4. Use of a composition according to any one of claims 1 to 3 for the preparation of an antioxidant ingredient.
5. Use according to claim 4, characterized in that the antioxidant ingredient is used in cosmetics.
6. A cosmetic comprising the composition according to any one of claims 1 to 3.
7. The cosmetic according to claim 6,
the composition is 0.1-10wt% based on the total weight of the cosmetic.
8. The cosmetic according to claim 6,
the cosmetic also comprises auxiliary materials.
CN202210938458.6A 2022-08-05 2022-08-05 Composition with antioxidation effect, application and cosmetic Pending CN115227616A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202210938458.6A CN115227616A (en) 2022-08-05 2022-08-05 Composition with antioxidation effect, application and cosmetic
CN202211405109.4A CN115501153A (en) 2022-08-05 2022-11-10 Cosmetic composition and use thereof
CN202211405101.8A CN115487120A (en) 2022-08-05 2022-11-10 Use of composition, cosmetic composition and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210938458.6A CN115227616A (en) 2022-08-05 2022-08-05 Composition with antioxidation effect, application and cosmetic

Publications (1)

Publication Number Publication Date
CN115227616A true CN115227616A (en) 2022-10-25

Family

ID=83678618

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210938458.6A Pending CN115227616A (en) 2022-08-05 2022-08-05 Composition with antioxidation effect, application and cosmetic
CN202211405101.8A Pending CN115487120A (en) 2022-08-05 2022-11-10 Use of composition, cosmetic composition and application thereof
CN202211405109.4A Pending CN115501153A (en) 2022-08-05 2022-11-10 Cosmetic composition and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202211405101.8A Pending CN115487120A (en) 2022-08-05 2022-11-10 Use of composition, cosmetic composition and application thereof
CN202211405109.4A Pending CN115501153A (en) 2022-08-05 2022-11-10 Cosmetic composition and use thereof

Country Status (1)

Country Link
CN (3) CN115227616A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327629A (en) * 2023-02-24 2023-06-27 华熙生物科技股份有限公司 Composition with antioxidation effect and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012222969A1 (en) * 2012-12-12 2014-06-12 Henkel Ag & Co. Kgaa Active ingredient combination for skin lightening II
CN114259415A (en) * 2021-12-01 2022-04-01 北京妍之素生物科技有限公司 Acid-transmitting skin-refreshing and repairing facial mask
CN114948834A (en) * 2022-07-15 2022-08-30 广州市丽泽化妆品有限公司 Soothing and moisturizing essence and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327629A (en) * 2023-02-24 2023-06-27 华熙生物科技股份有限公司 Composition with antioxidation effect and application thereof

Also Published As

Publication number Publication date
CN115487120A (en) 2022-12-20
CN115501153A (en) 2022-12-23

Similar Documents

Publication Publication Date Title
CN109414398B (en) Antioxidant composition for skin
WO2007029982A1 (en) Composition of skin external application for anti-aging
EP3741379A1 (en) Cosmetic composition comprising azadirachta indica leaf extract
KR101885195B1 (en) Cosmetic Composition with Fermentative Extract of Osmanthus fragrans
JP2001122757A (en) Active oxygen scavenger, antioxidant and cosmetic
CN115227616A (en) Composition with antioxidation effect, application and cosmetic
CN110448495A (en) A kind of cosmetic composition with collaboration antioxidant effect
KR100710657B1 (en) Whitening cosmetic composition containing dihydroquercetin
KR20110083480A (en) Superoxide dismutase, radical scavenger, and cell disorder inhibitor by oxidation
CN103945855A (en) Topical skin treatment composition comprising dendranthema indicum extract
KR102016062B1 (en) Callus extracts from Citrus junos Siebold ex Tanaka and Pyrus pyrifolia Nakai with Whitening and Anti-wrinkle effect
KR101086227B1 (en) Cosmetic Composition Comprising the extract of Lloydia triflora Bak as Active Ingredient
KR100967617B1 (en) Antioxidation and whitening cosmetic compositions containing extract of Isodon inflexus var. canescens
JP3231908B2 (en) Whitening cosmetics
CN110840785B (en) Cosmetic composition for improving skin aging or skin wrinkles
KR102041958B1 (en) Composition for skin-whitening containing mixed extracts as a active ingredients, and manufacturing method for composition and cosmetic composition
KR20180078869A (en) Composition for preventing, improving or treating photoaging of skin comprising DHPV
KR101640735B1 (en) Composition for improving skin wrinkle
JP2001354540A (en) Skin care preparation
JP6424137B2 (en) Active oxygen scavenger, anti-glycation agent, melanin production inhibitor and skin external preparation
US20160317430A1 (en) Cosmetic use of an extract of gymnema sylvestre
KR20130027598A (en) Cosmetic composition containing extracted rice wine lees for whitening effect
JP5667774B2 (en) Melanin production inhibitor, glutathione production promoter, hyaluronic acid production promoter, involucrin production promoter, and skin cosmetics
KR101640736B1 (en) Composition for improving skin wrinkle
CN108348435B (en) Anti-aging skin external composition containing cyanidin-3-O-glucoside and natto gum as effective components

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221025

WD01 Invention patent application deemed withdrawn after publication